SDS Biotech K.K. reported consolidated earnings results for the six months ended September 30, 2017. For the quarter, the company reported net sales of ¥6,442 million against ¥5,618 million a year ago. Operating income was ¥73 million against operating loss of ¥183 million a year ago. Ordinary income was ¥71 million against ordinary loss of ¥363 million a year ago. Net loss attributable to owners of parent was ¥111 million or ¥14.17 per basic share against ¥127 million or ¥16.25 per basic and diluted share a year ago. Income before income taxes was ¥69,636,000 compared to loss of ¥362,860,000 a year ago. Net cash provided operating activities of ¥869,253,000 compared to net cash used in operating activities of ¥202,114,000 a year ago. Purchase of property, plant and equipment was ¥107,370,000 compared to ¥93,345,000 a year ago. Purchase of intangible assets was ¥12,127,000 compared to ¥17,013,000 a year ago.

For the fiscal year ending March 31, 2018, the consolidated company expects net sales of ¥15,860 million, operating income of ¥1,440 million, ordinary income of ¥1,320 million and net income of ¥630 million or ¥80.45 per share.